Abstract
Background Machine learning-based facial and vocal measurements have demonstrated relationships with schizophrenia diagnosis and severity. Here, we determine their accuracy of when acquired through automated assessments conducted remotely through smartphones. Demonstrating utility and validity of remote and automated assessments conducted outside of controlled experimental settings can facilitate scaling such measurement tools to aid in risk assessment and tracking of treatment response in difficult to engage populations.
Methods Measurements of facial and vocal characteristics including facial expressivity, vocal acoustics, and speech prevalence were assessed in 20 schizophrenia patients over the course of 2 weeks in response to two classes of prompts previously utilized in experimental laboratory assessments: evoked prompts, where subjects are guided to produce specific facial expressions and phonations, and spontaneous prompts, where subjects are presented stimuli in the form of emotionally evocative imagery and asked to freely respond. Facial and vocal measurements were assessed in relation to schizophrenia symptom severity using the Positive and Negative Syndrome Scale.
Results Vocal markers including speech prevalence, vocal jitter, fundamental frequency, and vocal intensity demonstrated specificity as markers of negative symptom severity while measurement of facial expressivity demonstrated itself as a robust marker of overall schizophrenia severity.
Conclusion Established facial and vocal measurements, collected remotely in schizophrenia patients via smartphones in response to automated task prompts, demonstrated accuracy as markers of schizophrenia severity. Clinical implications are discussed.
Competing Interest Statement
Authors IGL, AA, VY and VK were employed and own shares at AiCure, LLC at the time of the study. Authors OP, MD, MM, LS, and BH are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Funding Statement
This study was funded by Merck & Co., Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Biomedical Research Alliance of New York
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated author list metadata
Data Availability
Due to privacy concerns, participants of this study did not agree for their data to be shared publicly.
